Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT01736150

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
Genzyme, a Sanofi Company (from the registry)
Registry
  • NCT NCT01736150
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01736150. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
Condition
Chronic Kidney Disease on Hemodialysis
Intervention (Drug)
Placebo
Intervention (Drug)
Sevelamer carbonate
Lead sponsor
Genzyme, a Sanofi Company (class: industry)

Record details

Record id
cardio:ct-nct01736150
Content hash
d562118ecd697d22a5a916b6616d4fc493c618ea58b1285bf901574f49fec23b